Etoposide (Vepesid)
Also known Etopophos, Etoposide phosphate, Toposar, or VP-16.
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Bone cancer
- Cancer of Unknown Primary
- Esophageal cancer
- Hepatobiliary cancer
- Hodgkin lymphoma
- Multiple myeloma
- Non-Hodgkin lymphoma
- Non-small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transplant conditioning regimens
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
References
- Drug index
- Chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Bone cancer medications
- Cancer of unknown primary medications
- Esophageal cancer medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Multiple myeloma medications
- Non-Hodgkin lymphoma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transplant medications